Intel has finalized the pricing for a major public offering of its common stock, raising the total value to $20 billion. The company is issuing 210,526,315 shares at a price of $95 per share. This move represents an increase from the initial $15 billion target announced previously by the firm, reflecting a significant capital injection as the company continues to navigate its long-term manufacturing and research objectives.
The offering is scheduled to close on August 12, 2026, provided that all customary closing conditions are met. Beyond the initial shares, Intel has granted underwriters a 30-day option to purchase an additional 31,578,947 shares at the same public offering price, minus standard underwriting discounts. This potential secondary tranche could further increase the total proceeds if the underwriters choose to exercise their option.
Intel expects to generate approximately $19.7 billion in net proceeds from the primary offering, after accounting for underwriting commissions and estimated expenses. The company has stated that these funds are intended for general corporate purposes. Specifically, the capital is earmarked to support ongoing investments in foundry operations and artificial intelligence development, which remain central to the company's current strategic roadmap.
A large consortium of financial institutions is managing the transaction. J.P. Morgan, Goldman Sachs, Morgan Stanley, and Citigroup are serving as the joint book-running managers for the offering. They are supported by a wide group of additional book-running managers, including Barclays, BofA Securities, BNP Paribas, and several others, alongside a team of co-managers tasked with overseeing the distribution of the shares.
The company has filed a registration statement on Form S-3 with the Securities and Exchange Commission to facilitate this offering. Intel has advised potential investors to review the official prospectus and related filings available through the SEC website for comprehensive details regarding the company's financial position and the risks associated with the investment. These documents outline the forward-looking nature of the company's manufacturing and research investments.